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We have previously shown that human papillomavirus virus-like particles (VLPs) are able to activate the Ras/MAP kinase pathway. Ras can
also elicit an anti-apoptotic signal via PI3-kinase so we investigated this further. Here we show that binding of VLPs from HPV types 6b, 18, 31,
35 and BPV1 results in activation of PI3-kinase. Activation was achieved by either L1 or L1/L2 VLPs and was dependent on both VLP–cell
interaction and correct conformation of the virus particle. VLP-induced PI3-kinase activity resulted in efficient downstream signaling to Akt and
consequent phosphorylation of FKHR and GSK3β. We also present evidence that PV signaling is activated via the α6β4 integrin. These data
suggest that papillomaviruses use a common receptor that is able to signal through to Ras. Combined activation of the Ras/MAP kinase and PI3-
kinase pathways may be beneficial for the virus by increasing cell numbers and producing an environment more conducive to infection.
© 2006 Elsevier Inc. All rights reserved.Keywords: Papillomavirus; Integrin; VLP; PI3-kinase; Akt; FKHR and GSK3βIntroduction
Papillomaviruses (PVs) are non-enveloped dsDNA tumor
viruses that cause a range of proliferative lesions upon infection
of epithelial cells (Howley, 1996). These viruses are the
causative agent of warts (plantar, laryngopharyngeal and
genital) (Bosch et al., 1995) and the critical factor in the
formation of anogenital cancer (Zur Hausen, 1994). Many
aspects of the PV life cycle have been difficult to elucidate due
to the lack of robust in vitro replication systems. However, the
advent of virus-like particle (VLP) technology has partially
overcome this problem and allowed investigation of the early
events of infection.
The first step in viral infection is the binding of the virus to
its receptor upon a host cell. The quest to identify cellular
receptors for papillomavirus has so far yielded a few different
candidates. It is known the receptor is a protein and that a wide
variety of cells facilitate binding (Qi et al., 1996). Also, virus
particles from different PV species or subtypes are able to
interfere with another's binding (Muller et al., 1995; Roden et⁎ Corresponding author. Fax: +61 7 3240 5946.
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doi:10.1016/j.virol.2006.05.002al., 1994) and conservation of the L1 gene between PV species
suggests that a common receptor is utilized. The α6β4 integrin
complex and heparan sulfate proteoglycans (HSPGs) have been
identified as receptors for PV (Bousarghin et al., 2003; Combita
et al., 2001; Drobni et al., 2003; Evander et al., 1997; Giroglou
et al., 2001; Joyce et al., 1999; McMillan et al., 1999; Selinka et
al., 2002, 2003; Shafti-Keramat et al., 2003; Yoon et al., 2001),
although conversely there are recent data to suggest not all PVs
may use these receptors. Models of infection using PV types 11
and 31 indicate that these viruses are able to infect cells that do
not posses α6β4 or heparan sulfate, respectively (Patterson et
al., 2005; Shafti-Keramat et al., 2003).
There is mounting evidence that virus receptor attachment is
not merely a conduit for entry into the cell but is also a means of
activating cellular signaling pathways to promote viral
infection. For example, HIV binding is known to cause
phosphorylation of Pyk2 (Davis et al., 1997) as well as the
activation of calcium signaling pathways (Weissman et al.,
1997). Measles virus binding directly activates NFκB (Helin et
al., 2001) as well as signaling to stop proliferation (Erlenhoefer
et al., 2001). Furthermore, EBV is able to activate NFκB via
interaction with its receptor, CD21, to enhance transcription
from the EBNA2 promoter, Wp (Sugano et al., 1997). We have
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Ras/MAP kinase pathway (Payne et al., 2001). Other viruses are
also able to activate this pathway, including JC virus (Querbes
et al., 2004), SIV and HIV (Popik et al., 1998; Popik and Pitha,
1998), CMV (Boyle et al., 1999) and HHV8 (Naranatt et al.,
2003). For PV, activation results in a binding-mediated
induction of c-myc mRNA and induction of DNA synthesis in
these cells.
It is well known that activation of Ras not only induces a
growth signal to cells via MAP kinases but also elicits an anti-
apoptotic signal via the PI3-kinase pathway (Brazil and
Hemmings, 2001; Nicholson and Anderson, 2002; Scheid and
Woodgett, 2001, 2003). Activated PI3-kinase has been known
for some time to rescue cells from a variety of apoptotic insults
and was first recognized by Yao and Cooper (1995) as being
required to mediate the anti-apoptotic effect of nerve growth
factor. Phosphorylation of downstream mediators such as BAD,
forkhead transcription factors (FKHR) and glycogen synthase
kinase 3β (GSK3β) via Akt/PKB provide a mechanism for this
anti-apoptotic effect and play an important role in control of the
cell-cycle (for a review, see Liang and Slingerland, 2003).
The PI3-kinase/Akt pathway is known to be stimulated by a
number of viruses following infection including polyomavirus
(Whitman et al., 1985), EBV (Darr et al., 2001; Swart et al.,
2000), HBV (Shih et al., 2000) and cytomegalovirus (Johnson
et al., 2001). Viral proteins produced by these viruses during
infection activate this important cell regulatory pathway to aid
in viral replication, promote cellular survival by inhibiting
apoptosis and are also implicated in the reactivation of viruses
from latency. However, both adenovirus and HIV are able to
induce signaling upon initial binding to their cellular receptors
(Briand et al., 1997; Li et al., 1998). Interestingly, adenovirus
binds to the αV integrin and viral endocytosis was inhibited by
blocking PI3-kinase activation (Li et al., 1998).
We therefore wanted to know whether PV-activated Ras was
also able to stimulate PI3-kinase and result in transmission of
known survival signals to the cells. Importantly, we also wished
to know whether this signal was propagated by PV binding to
the α6β4 integrin. This study shows that binding of VLPs from
several different PV types, both human and animal, results in
activation of PI3-kinase. Both L1 and L1/L2 VLPs were able to
activate PI3-kinase and activation was dependent on the ability
of the VLP to interact with cells and on the correct conformation
of the virus particles. VLP-mediated activation of PI3-kinase
resulted in efficient downstream signaling with the activation of
Akt and consequent phosphorylation of FKHR and GSK3β.
Finally, we examine if PV signaling is activated through the
α6β4 integrin.
Results
Papillomavirus virus-like particles activate PI3-kinase
We have previously shown that treating cells with HPV6b L1
VLPs for as little as 5 min results in the activation of the Ras-
MAP kinase pathway and stimulation of cell proliferation
(Payne et al., 2001). Activation of Ras is also known to activatePI3-kinase to promote cell survival via anti-apoptotic signals
(Brazil and Hemmings, 2001; Nicholson and Anderson, 2002;
Scheid and Woodgett, 2001, 2003). Therefore, to further
elucidate the activation of signaling pathways by papillomavi-
rus, we investigated the possibility that PV-VLPs were able to
activate the PI3-kinase pathway.
We initially treated serum-starved A431 cells (5 × 106) with
100 ng of PV VLPs containing either L1/L2 (BPV, HPV-16, -31
and -35) or only L1 (HPV-18 and -6b) to assess the level of PI3-
kinase activity. This amount of VLP was found to be the lowest
required to give a signal (data not shown) and equates to
approximately 600 viral particles per cell, based on VLPs
having an MWof 1.98 × 107 (360 L1 molecules/VLP at 55 kDa/
L1). Hence, 1.98 × 107 g of VLPs equals 1 mol and therefore
6 × 1023 particles (Avogadro's number). From this we deduce
that 100 ng = 3 × 109 particles, which is 600 particles per cell in
our assay of 5 × 106 cells. Previous data have shown that there
are around 1 × 104 receptors/cell using CV-1 cells (Qi et al.,
1996) and 2 × 104 receptors using HeLa cells (Volpers et al.,
1995), hence our assay does not reach the point of receptor
saturation. Following treatment, cell extracts were obtained,
PI3-kinase immunoprecipitated and the purified kinase mixed
with bovine brain extract in the presence of [γ-32P]ATP. The
conversion of phospholipid substrate to phosphatidylinositol-
3,4,5-trisphosphate by PI3-kinase was measured via thin-layer
chromatography and phosphorimagery. Quantification of spots
was performed using ImageQuant™ software and local average
background correction applied. Correction for load was
performed using quantified western blot data from immuno-
precipitates. This method is a well-established and sensitive
way of assaying for PI3-kinase activity with 2- to 10-fold
increases seen to be significant (Okkenhaug et al., 2002; Nadler
et al., 2001; Street et al., 2005). Exposure of cells to VLPs
resulted in the activation of PI3-kinase by 3.3- to 5-fold over
mock-infected cells (Fig. 1A), depending on the VLP used. This
compares favorably with the 9.6-fold activation observed when
cells were treated with 10% serum. The activation of PI3-kinase
was not dependent on PV type, or the presence of L2 in the
VLPs, as L1-only VLPs (HPV18 and -6b; Fig. 1B) were able to
activate PI3-kinase as well as L1/L2 VLPs (BPV, HPV-16, -31
and -35).
PV VLP interaction with cells and VLP integrity is critical for
activation of PI3-kinase
To eliminate the possibility that PI3-kinase was being
activated by a means other than VLP binding, we undertook a
number of control experiments. Pre-treatment of HPV6bL1
VLPs with an anti-HPV6b monoclonal antibody (MC8) resulted
in an 80% reduction in PI3-kinase activation whereas treatment
with a non-specific, isotype-matched control antibody showed
no effect (Fig. 1B). We have previously used this antibody to
block VLP-induced cell proliferation (Payne et al., 2001). This
suggested that the activation of PI3-kinase required the
interaction of VLPs with the cell. To ascertain if VLP structural
integrity was required for activation, we boiled VLPs for 5 min.
We observed that boiling VLPs reduced the level of PI3-kinase
Fig. 1. PV VLPs activate PI3-kinase and integrity and interaction with cells are
critical. (A) Serum-starved A431 cells (5 × 106) were treated with VLPs (100 ng)
for 60 min at 37 °C. (B) Serum-starved A431 cells were treated with 100 ng of
HPV6b VLPs, VLPs pre-blocked with an anti-L1 monoclonal antibody or a non-
specific isotype matched antibody, or VLPs boiled for 5 min. For all samples,
PI3-kinase was immunoprecipitated from cell extracts and an aliquot was
western blotted for PI3-kinase to control for enzyme input. PI3-kinase activity
from the remaining immunoprecipitate was measured by assaying lipid substrate
conversion to phosphatidylinositol-3,4,5-trisphosphate using incorporated
radiolabeled ATP. Phospholipids were separated by thin-layer chromatography
and radioactivity measured by phosphorimager analysis. Positive control cells
were treated with 10% serum and negative control cells an equivalent amount of
VLP diluent (PBS). Data are representative of two or more independent assays.
Numbers indicate load-corrected fold increase over control or normalized
percent activity compared to VLP. (C) Averaged raw data (background
corrected) for all control, serum and VLP spots in panels A and B.
321T. Fothergill, N.A.J. McMillan / Virology 352 (2006) 319–328activation by 50% (Fig. 1B). This was consistent with the
reduced level of activation of the Ras-MAPK pathway we had
previously observed (Payne et al., 2001). We speculate that
incomplete denaturation of the VLP by boiling is the reason
why we did not see a further reduction, with residual pentameric
L1 possibly leading to cross-linking and minor activation of the
receptor.
Akt is activated by VLPs
We next wished to ascertain if downstream effectors in the
PI3-kinase pathway were activated by VLP treatment. Activa-
tion of PI3-kinase has been shown to result in recruitment of the
kinase PDK-1 to the plasma membrane, where it is activated
and phosphorylates Akt (Alessi et al., 1997; Burgering and
Coffer, 1995; Stokoe et al., 1997). Therefore, we treated serum-starved A431 cells with PV VLPs from HPV types 18, 16, 6b
and BPV1 for various times before ascertaining Akt activation.
For these experiments, we wished to maximize the signal by
engaging every receptor with a VLP. Although no data is
available to indicate the number of receptors on A431 cells,
flow cytometry analysis of α6β4 expression suggests they have
approximately the same number as CV-1 cells, around 1 × 104/
cell (Payne et al., 2001). Therefore, we used 1 μg VLP
(∼3 × 1010 particles) per 1.2 × 106 cells. All the VLPs tested
were able to activate Akt as indicated using a phospho-specific
(S473) Akt antibody, as did 10% serum treatment for 20 min
(Fig. 2A). Maximal phosphorylation appeared to be at around
10–20 min although we also noted a somewhat biphasic
activation. Activity was observed to decline gradually after
20 min and then rise again with a second peak occurring around
120 min (data not shown and Fig. 3). This temporal regulation
was observed with all VLP types tested. We also observed some
minor phosphorylation of Akt on T308 (data not shown).
Once again, VLP–cell contact was required for this activity
as pre-blocking HPV16 or BPV1 VLPs with the H16.V5 (anti-
HPV16) or B1.A1 (anti-BPV) monoclonal antibodies, respec-
tively, reduced Akt phosphorylation to background levels (Fig.
2B). These antibodies have both been shown to inhibit VLP
binding to cells via the hemagglutination inhibition assay
(Roden et al., 1996) and in vitro neutralization of the focus-
forming assay (Christensen and Kreider, 1993; Roden et al.,
1997). Pre-blocking with a non-specific monoclonal antibody
had little impact on VLP-induced Akt activation (89% and 95%
binding compared to positive control), whereas blocking with
H16.V5 and B1.A1 antibodies reduced activation to back-
ground levels. VLP integrity was also required for Akt
activation, as denaturing HPV16 and BPV VLPs, by boiling
for 30 min, reduced phosphorylation to background levels.
Next, we wished to address the issue of how activation of
Akt was occurring as there are several studies suggesting PDK-
1-independent activation of Akt is possible (Basso et al., 2002;
Yano et al., 1998). Therefore, to ensure that PV VLPs were
activating Akt via PI3-kinase, we used the potent and specific
PI3-kinase inhibitor, wortmannin. We also decided to use BPV1
L1/L2 VLPs for all subsequent experiments as they were
observed by electron microscopy to contain the best quality
particles of available preparations. Also, there was no
significant difference between L1 and L1/L2 VLPs in terms
of signal intensity and duration. Cells were pre-treated with
200 nM wortmannin for 20 min prior to the addition of BPV1
VLPs. As expected, wortmannin completely inhibited the
activation of Akt by serum (Fig. 3) and caused potent inhibition
of VLP-mediated activation of Akt, thus indicating a require-
ment for PI3-kinase.
Cell cycle mediators downstream from Akt are activated by
VLPs
There are a growing number of proteins that are activated
downstream of Akt that regulate cell cycle progression and cell
survival. Two of the best studied are FKHR and GSK3β. When
phosphorylated by Akt, these proteins have been shown to
Fig. 2. Akt is activated by PV VLPs. Signaling is removed by VLP denaturation and antibody blockade. (A) A431 cells (1.2 × 106) were serum-starved overnight
before treatment with 1 μg VLPs for 10-30 min or 10% serum for 20 min as positive control. (B) HPV16 and BPV1 VLPs were pre-blocked with H16.V5 (anti-
HPV16) and B1.A1 (anti-BPV1) monoclonal antibodies, non-specific control monoclonal antibody, or were denatured by boiling prior to treatment of serum-starved
A431 cells. Following treatment, cells were solubilized in loading buffer and western blot performed using anti-pAkt (S473) or anti-Akt antibodies. Data are
representative of two or more independent assays. Numbers indicate load-corrected normalized percent activity compared to VLP.
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effect (for a review, see Liang and Slingerland, 2003), thus
supporting our previous data that VLP treatment induced
cellular DNA synthesis (Payne et al., 2001). We wished toFig. 3. Akt activation is mediated via PI3-kinase and FKHR and GSK3β, cell
cycle regulators downstream from Akt, are phosphorylated. Serum-starved
A431 cells (1.2 × 106) were treated with 1 μg BPV1 or HPV18 VLP for 20 or
120 min as indicated. Wortmannin-treated cells were pre-treated with 200 mM
wortmannin for 20 min prior to addition of VLP. Cells were solubilized in
loading buffer and western blotted using anti-pAkt (S473), anti-Akt, anti-
pGSK3β or anti-pFKHR antibodies. After probing, the membrane was
Coomassie stained to provide an additional loading control. Numbers indicate
fold increase compared to serum-positive control after normalization to negative
controls.determine the status of these downstream effectors upon VLP
stimulation. As expected, treatment of cells with 10% serum for
20 min resulted in a robust activation of both FKHR and
GSK3β as determined using phospho-specific antibodies (Fig.
3). Cells treated with BPVl L1/L2 VLPs were also observed to
have increased levels of phospho-FKHR and GSK3β at both
20 min and to a lesser extent at 120 min. To show that activation
was specifically regulated via PI3-kinase, we also pre-treated
cells with wortmannin. This resulted in the complete loss of
activation of both FKHR and GSK3β in all treatments.
Activation of the PI3-kinase pathway by PV VLP is mediated
through α6β4 integrin
PV has been shown to readily bind to the α6β4 integrin, and
expression of α6 on B cells confers the ability to bind PV VLPs
(Evander et al., 1997; McMillan et al., 1999). It was therefore
proposed as a PV receptor. However, it is clear that heparan
sulfate proteoglycans can also support PV VLP binding,
although they have been shown to not be required for infection
(Patterson et al., 2005). PVappears to interact with a number of
cell surface molecules and so we decided to investigate whether
PV signaling through the PI3-kinase pathway was being
mediated by α6β4 integrin.
In order to show that α6β4 integrin was required for
signaling, we utilized two different methods, RNA interference
and specific antibody blocking. Firstly, we designed an siRNA
and tested its ability to down-regulate the cell surface
expression of the α6 integrin. We achieved a 50% loss of cell
surface α6 integrin (Fig. 4B), as determined by mean
fluorescence intensity, compared to control stained cells,
whereas treatment of cells with a control siRNA resulted in
only a 16.6% reduction in α6 expression (Fig. 4C). Thus, we
Fig. 5. Pre-treating A431 cells with function-blocking, antibodies against α6 and
β4 integrins prevents PV VLP-induced Akt activation. Cells were pre-treated
with anti-α6 and anti-β4 integrin antibodies or an equivalent amount of control
isotype-matched antibody at 4 °C for 30 min prior to stimulation for 20 min with
BPV VLP or 10% serum as positive control. Cells were solubilized and western
blot performed using anti-pAkt (S473) or anti-Akt antibody as per previous Akt
experiments.
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the level of cell surface α6 integrin. We next examined the
phosphorylation of Akt to determine the signaling capability of
the siRNA-treated cells. We observed that the level of pAkt-
S473 was reduced to background levels in cells treated with α6
siRNA, whereas control GFP siRNA had no effect (Fig. 4A). To
ensure this was not due to non-α6 integrin events, we tested a
known activator of the α6β4 integrin, laminin, and observed
that laminin-mediated activation of Akt was also reduced in α6
siRNA-treated cells. Interestingly, there was also a decrease in
Akt activation in α6 siRNA-treated cells stimulated with serum,
suggesting that a significant part of serum signaling is via the α6
integrin. However, this reduction did not reach the background
levels observed with VLP and laminin treatment.
Secondly, we showed the α6β4 integrin was transmitting
the VLP-mediated signal by using antibody blockade. The
anti-α6 (GoH3 clone) and anti-β4 (Asc-9 clone) antibodies
have previously been shown to block cells expressing α6β4
integrin from binding to laminin-5 (Kikkawa et al., 2000;
Stahl et al., 1997). They have also been used as function-
blocking antibodies while, importantly, being observed not to
block TNFα-induced apoptosis or activate NFκB (Weaver et
al., 2002), suggesting an inability to stimulate the integrins. In
addition, we have previously shown that the GoH3 antibody is
able to block VLP binding to cells by 63% (Evander et al.,Fig. 4. siRNA against α6 integrin reduces PV VLP-induced activation of Akt.
(A) A431 cells were transfected with α6 siRNA or GFP control siRNA as
described. BPV VLPs, laminin or serum was added for 20 min before cells were
solubilized and western blot performed using anti-pAkt (S473) or anti-Akt
antibody. (B) siRNA transfected cells were analyzed by flow cytometry using
FITC-labeled antibodies; (a) α6 siRNA transfected cells stained with control
antibody; (b) α6 siRNA transfected cells stained with anti-α6 antibody; (c)
mock transfected cells stained with anti-α6 antibody. The α6 siRNA reduced
surface α6 levels by 50% (b) compared to controls (a and c). (C) siRNA
transfected cells were analyzed by flow cytometry using FITC-labeled
antibodies; (a) mock transfected cells stained with control antibody; (b) control
siRNA transfected cells stained with control antibody; (c) control siRNA
transfected cells stained with anti-α6 antibody; (d) mock transfected cells
stained with anti-α6 antibody.1997). Therefore, we pre-blocked A431 cells at 4 °C with
both these antibodies before exposure to PV VLPs and
observed the relative activation of Akt. Under these condi-
tions, specific blockade of α6 and β4 led to profound loss of
Akt activation, whereas isotype-matched control antibodies
had no effect (Fig. 5).
Discussion
This study clearly shows that PV can activate the PI3-kinase
pathway and that this occurs via the α6β4 integrin. This
phenomenon is not limited to a single PV type and is true for
both human and bovine PV VLPs. Indeed, we show that five
different PV VLP types were able to induce PI3-kinase and Akt
signaling, suggesting a common receptor is utilized. Previously,
we and others have proposed the α6β4 integrin as a potential
PV receptor (Evander et al., 1997; McMillan et al., 1999; Yoon
et al., 2001). This would be consistent with our findings, as the
ligation of α6β4 with laminin or polystyrene bead-conjugated
anti-β4 antibodies (to promote integrin clustering) has been
shown to result in the activation of Ras and PI3-kinase
(Mainiero et al., 1997; Tang et al., 1999). Our evidence
suggesting that activation of the PI3-kinase pathway by PV
VLPs is induced via α6β4 integrin uses both an siRNA
knockdown approach as well as function-blocking antibodies
against the α6β4 complex. The α6 siRNA also inhibited
signaling from laminin, a known ligand of α6β4. Although
siRNA treatment only reduced cell surface α6 expression by
50%, signaling was reduced to background levels. This fits with
current thinking that for signaling to occur in many systems a
critical, threshold concentration of cell surface receptors must
be reached in order to allow clustering of the receptor/signaling
complex. We speculate that the siRNA-mediated reduction
resulted in the concentration of α6β4 falling below this
threshold level.
Heparan sulfate (HS) can also act as a primary attachment
receptor for PV VLPs (Bousarghin et al., 2003; Combita et al.,
2001; Drobni et al., 2003; Giroglou et al., 2001; Joyce et al.,
1999; Selinka et al., 2002, 2003; Shafti-Keramat et al., 2003).
Heparan sulfate proteoglycans (HSPGs) play a crucial role in
growth regulation by assembling signaling complexes and
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example, syndecan-1 has been shown to enhance the activation
of Ras-MAPK and PI3-kinase/Akt pathways by hepatocyte
growth factor via the Met receptor in multiple myeloma cells
(Derksen et al., 2002). Syndecans are intimately associated with
integrins and syndecan-1 has been shown to be involved in PV
binding (Shafti-Keramat et al., 2003). At present, it is not
known exactly how the PV signal is mediated and our work
does not rule out a role for HSPGs in viral signaling. We
hypothesize that HSPGs are used for initial attachment and/or
concentration of the virus around a more specific receptor such
as the α6β4 integrin. Notably, both α6β4 and HS have been
shown to be redundant for infection in at least two PV types (11
and 31, respectively), suggesting not all PV may use these
receptors (Patterson et al., 2005; Shafti-Keramat et al., 2003) or
that this interaction is not critical for overall replication.
Both L1 and L1/L2 VLPs are able to signal cells. This
suggests L1 is the viral protein responsible for the activation of
signal transduction. Moreover, as we are using VLPs, an early
viral replication event cannot be the cause of PI3-kinase
activation, but rather a direct interaction with the cell is
required. We also show that intact virus particles and virus
receptor interactions are required for PI3-kinase and Akt signals
to be generated. Denaturing VLPs by boiling significantly
reduced PI3-kinase activation and Akt phosphorylation, which
fits well with our previous data showing boiling markedly
reduced cell proliferation (Payne et al., 2001). We note that 5-
min boiling reduced the PI3-kinase signal by 50%. However,
the PI3-kinase signal was not completely attenuated, suggesting
either denaturation was incomplete or that linear L1 is able to
activate the signal, albeit at significantly reduced levels than
intact VLPs. Others have shown small linear peptides of L1 and
L2 are able to bind to heparan sulfate and block PV infection
(Bousarghin et al., 2003, 2004), although we do not know if
these small peptides could activate signaling. In support for lack
of denaturation, we show that boiling VLPs for an extended
period of 30 min was able to completely eliminate Akt
phosphorylation. Additionally, it has been observed by electron
microscopy that boiling VLPs for 20 min completely removes
tertiary structure (Payne et al., 2001). We speculate that
complete denaturation of the VLPs and L1 pentamers requires
this prolonged treatment with only partial denaturation
occurring after 5 min of boiling.
PI3-kinase is known to control a number of different
pathways through its ability to convert membrane phospholi-
pids into the active phosphatidyl-inositol 3,4,5 trisphosphate
(PtdIns(3,4,5)P3). The blockade of apoptosis, mediated via Akt,
being the best described. Here we show that VLP binding is able
to induce the phosphorylation of Akt via PI3-kinase, leading to
the activation of downstream effectors. Interestingly, Akt
activation was observed to be somewhat biphasic. This is
similar to the biphasic VLP-mediated Erk activation we have
previously noted (Payne et al., 2001). There are a number of
proteins signaling from Akt that are involved in the control of
apoptosis and which have also been shown to be intimately
linked to regulation of the cell cycle. FKHR and GSK3β are two
such proteins. Upon phosphorylation, FKHR is translocatedfrom the nucleus by the protein 14-3-3 and is no longer able to
act as a transcriptional regulator. This prevents the production of
apoptosis inducers such as Fas as well as proteins involved in
cell cycle control including p27. GSK3β also plays an
important role in cell cycle regulation. It acts by phosphory-
lating the short-lived cyclin D and c-Myc, promoting their
nuclear export and consequent ubiquitin-mediated proteolysis.
However, when phosphorylated, GSK3β is unable to act as a
kinase and consequently c-Myc and cyclin D levels are
stabilized. This promotes progression through G1 phase.
Signaling through the Ras-MAPK pathway also stimulates c-
Myc and cyclin D and thus Akt acts in concert to produce a
sustained growth signal as well as an anti-apoptotic signal.
Therefore, signaling by PV VLPs would provide the cell with
both anti-apoptotic and pro-growth signals, via the PI3-kinase
and Ras-MAPK pathways, setting the cell up to be receptive for
viral replication.
A more speculative possibility is that PVactivates PI3-kinase
to modulate the immune system and limit proinflammatory
responses. Indeed, PI3-kinase/Akt signalling has been sug-
gested to play an important role in limiting immune responses
(Fruman and Cantley, 2002). It has been reported that activation
of the PI3-kinase/Akt pathway limits the proinflammatory
effects of LPS in cultured monocytes (Guha and Mackman,
2002), whereas others have suggested that PI3-kinase activation
may provide a negative feedback mechanism that prevents
excessive innate immune responses (Fukao and Koyasu, 2003).
Moreover, activation of the PI3-kinase pathway has been
observed to suppress proinflammatory and apoptotic processes
in response to sepsis and/or inflammatory injury (Williams et
al., 2004). Indeed, VLPs are unable to activate Langerhans cells,
which has been suggested as a reason for their poor
immunogenicity (Fausch et al., 2002).
In summary, the results presented here provide the first
evidence that PV VLPs are capable of stimulating the PI3-
kinase/Akt pathway and can activate key downstream effectors.
This supports previous data that demonstrated their ability to
induce the Ras-MAPK pathway leading to cell growth. Our
results also show that these signaling pathways are mediated via
the α6β4 integrin, which further suggests it is the primary PV
receptor. Activation of these important growth regulatory
pathways could be beneficial by producing an environment
more suitable to infection and may be a requirement for the
virus to complete its life cycle.
Materials and methods
Cells lines and virus-like particles
A431 (human epidermoid carcinoma) cells were grown in
Dulbecco's modified Eagle's medium (DMEM) (Gibco BRL,
Melbourne, Australia) supplemented with 10% heat-inactivated
fetal bovine serum (JRH Biosciences, Lenexa, KS), 100 U/mL
penicillin G, 100 U/mL streptomycin and 2.9 mg/mL glutamine
(Full DMEM) and maintained in a humidified incubator at
37 °C with 5% CO2. HPV6b L1 VLPs were produced in Sf9
cells by recombinant baculovirus and purified as previously
325T. Fothergill, N.A.J. McMillan / Virology 352 (2006) 319–328described (Qi et al., 1996). To further purify VLPs and remove
any contaminating L1 monomers and pentamers in our HPV6b
VLP preps, we used an S300 (Sephacryl S300-Pharmacia
Biotech) size-exclusion column using gravity flow. The packed
column was washed three times with 10 mL equilibration buffer
(PBS, 0.1 mM CaCl2, 0.01 mM MgCl2). Buffer level was
brought to resin interphase and 800 mL purified VLP from the
baculovirus prep was run into column bed. The column was
topped with equilibration buffer and 1 mL void volume
collected. Fractions of 250 μL were collected and analyzed by
Bio-Rad protein assay and western blot using a monoclonal
antibody against HPV6b (MC8). The fractions containing the
intact virions were pooled and centrifuged at 60000 rpm for 1 h
at 4 °C using a TLA100.3 rotor in a Beckman TL-100
ultracentrifuge. The pellet containing the purified VLP virions
was resuspended in 100 mL equilibration buffer. BPV1 L1/L2,
HPV 16 L1/L2, 31 L1/L2, 35 L1/L2 and 18 L1 VLPs were a
generous gift from Ray Viscidi, Johns Hopkins University
School of Medicine, Baltimore, MD. They were prepared in
Trichoplusia ni (High Five) cells (Invitrogen, Carlsbad, CA)
from recombinant baculoviruses expressing the L1 and/or L2
genes of the respective virus and were purified by density
gradient ultracentrifugation and column chromatography tech-
niques as described previously (Viscidi et al., 2003).
PI3-kinase immunoprecipitations
To immunoprecipitate PI3-kinase, A431 cells were grown
to 80–90% confluence in 10-cm dishes before cells were
incubated overnight in serum-free DMEM prior to stimulation.
VLP blocking was performed by pre-incubating with 1 μL
anti-HPV6b L1 monoclonal antibody (MC8) (a gift from Wen-
Jun Liu, University of Queensland, Brisbane, Australia) or
1 μL isotype-matched control antibody for 1 h at 37 °C prior to
addition to cells. VLP denaturation was performed by boiling
for 5 min prior to addition to cells. Normal or blocked/
inactivated VLP (100 ng) or 10% serum as a positive control
were added to medium and incubated at 37 °C for the required
time period. Treated cells were then placed on ice and washed
three times with 10 mL ice-cold PBS supplemented with 1 mM
DTT, 1 mM PMSF and 1 mM NaVO4. Cells were lysed in
1 mL of lysis buffer (20 mM Tris–HCl pH 7.4, 137 mM NaCl,
1 mM MgCl2, 1 mM CaCl2, 10% glycerol, 1% NP40, 1 mM
DTT, 1 mM PMSF and 1 mM NaVO4) and incubated at 4 °C
for 20 min. Extracts were centrifuged at 10,000 × g for 15 min
at 4 °C and supernatants collected. Extracts were then
incubated with 2 μL anti-PI3K (p85 subunit) antibody (New
England Biolabs, Beverly, MA) at 4 °C for 2 h before the
addition of 40 μL protein-G sepharose (50% suspension in
PBS, freshly blocked with BSA) (Amersham Pharmacia,
Castle Hill, Australia) and incubation continued overnight.
PI3-kinase was collected by centrifuging at 12000×g for 5 s at
4 °C and washed three times with 1 mL ice-cold 1% NP40-
PBS, 1 mL ice-cold 0.5 M LiCl in 100 mM Tris pH 7.4 and
1 mL ice-cold 100 mM NaCl in 10 mM Tris pH 7.4,
respectively, before being resuspended in 1 mL of 100 mM
NaCl in 10 mM Tris pH 7.4.PI3-kinase activity assays
A 100-μL aliquot of freshly immunoprecipitated PI3-kinase
was taken for western blot analysis to allow for normalization of
enzyme load in the assay. The remaining immunoprecipitate
was then resuspended in 30 μL room temperature 20 mM
MgCl2, 100 mM NaCl, 10 mM Tris–HCl pH 7.4 containing
1 μCi [γ-32P]ATP and 20 μL of 1 mg/mL bovine brain extract
(Sigma, Castle Hill, Australia) (dissolved in 25 mM HEPES pH
7.4, 1 mM EDTA). The reaction mix was incubated at room
temperature for 10 min before the addition of 100 μL 1 M HCl
and 160 μL chloroform/methanol (1:1). The mixture was
vortexed briefly and centrifuged at RT for 1 min at 12,000×g.
The upper phase was discarded and 20 μL of lower phase was
spotted onto a thin-layer chromatography (TLC) plate, dried
and TLC was performed.
Thin-layer chromatography
TLC was performed using silica gel 60 pre-coated glass-
backed TLC plates (EM Science, Gibbstown, NJ). Plates were
prepared by immersion in fresh oxalate solution (1.3%
potassium oxalate, 40% methanol, 2 mM EDTA) for 30 min
before being baked for 10 min in a pre-heated 100 °C oven.
Samples were separated by TLC using 50% chloroform, 40%
methanol, 1.7% NH4OH as solvent. Radioactivity was
measured and quantified using a STORM phosphorimager
and ImageQuant software (Molecular Dynamics). Background
correction using local average was applied.
Activation of Akt, GSK3β and FKHR
A431 cells were grown to 80% confluence in 6-well tissue
culture plates before being serum-starved overnight in 1 mL per
well serum-free DMEM. Wortmannin-treated cells were pre-
incubated with 200 mM wortmannin (Sigma, Castle Hill,
Australia) in DMEM for 20 min prior to addition of stimulant.
Antibody pre-blocking of A431 cells was performed using
mouse anti-human CD49f (α6 integrin) and mouse anti-human
CD104 (β4 integrin) function-blocking antibodies (clones NKI-
GoH3 and ASC-9, respectively) (Chemicon, Temecula, CA).
Cells were treated with 1 μg of each blocking antibody or 2 μg
control serotype-matched mouse IgG2a antibody (Bethyl
Laboratories, Montgomery, TX) in 1 mL DMEM per well for
30 min at 4 °C. These antibodies were dialysed against PBS for
1 h at RT using a 0.22-μM PES dialysis membrane (Millipore,
Sydney) to remove azide and other additives that could affect
signaling.
VLP blocking was performed by pre-incubating 1 μg VLP
with 4 μL H16.V5 (anti-HPV16) or B1.A1 (anti-BPV1) mouse
ascites monoclonal antibodies (gifts from Neil Christensen,
Penn State College of Medicine, Hershey, PA), or 4 μL of
control anti-PKR mouse ascites monoclonal as a negative
control, for 1 h at 4 °C prior to addition to cells. VLP
denaturation was performed by boiling for 30 min prior to
addition to cells. The desired stimulant was then added to the
medium and incubated with cells for the required time, 10%
326 T. Fothergill, N.A.J. McMillan / Virology 352 (2006) 319–328fetal bovine serum (Gibco BRL) and/or 10 μg laminin (from
mouse EHS-sarcoma) (Boehringer Manheim, GmbH, Ger-
many) treatment for 20 min being used as positive controls.
Cell extracts were prepared by solubilising cells in 200 μL
SDS–PAGE loading buffer and collecting in tubes.
siRNA interference
An siRNA target sequence was identified with the Ambion
siRNATarget Finder program (http://www.ambion.com/techlib/
misc/siRNA_finder.html) against the human α6 integrin mRNA
sequence (NM_000210) as 5′-AAGGTGGCTGCGGT-
AGCAGCA-3′ and duplex siRNA oligos with 3′UU overhangs
supplied by Proligo (Lismore, Australia). Control siRNAs
against GFP (sense 5′-GCACGACUUCUUCAAGUCCUU-3′,
AS 3′-UUCGUGCUGAAGAAGUUCAGG-5′) and HPV16 E6
(sense 5′ CACGUAGAGAAACCCAGCUUU-3′, AS 3′-UUG-
UGCAUCUCUUUGGGUCGA-5′) were also obtained from
Proligo. Prior to transfection, A431 cells (90% confluent in 6-
well plates) were washed once in PBS and put into 800 μL
Optimem (Invitrogen, Sydney) low-serum medium. siRNAs
(100 nM) were transfected into A431 cells using Oligofectamine
(Invitrogen, Sydney) according to the manufacturer's instruc-
tions. After 5 h, cells were washed once, placed into full DMEM
medium and grown overnight. The following day, cells were
washed and placed into serum-free DMEM overnight prior to
analysis of Akt activation or flow cytometry.
Western blotting and flow cytometry
PI3-kinase western blots were performed to control for
enzyme amount using 100 μL immunoprecipitate, which was
resuspended in 20 μL SDS–PAGE loading buffer. Protein was
separated using a 10% SDS–PAGE gel and transferred to
PVDF. Akt, phospho-Akt, phospho-GSK3β and phospho-
FKHR western blots were performed by separating 20–30 μL
of cell extract using a 12% SDS–PAGE gel and transfer to
PVDF membrane. Anti-PI3-kinase (p85 subunit), anti-Akt, anti-
phospho Akt (Ser473 and Thr308), anti-phospho GSK3β and
anti-phospho FKHR antibodies were all sourced from Cell
Signalling Technologies (Beverly, MA) and used at 1:1000
dilution in TBS-T/5% BSA overnight at 4 °C. Membranes were
washed twice for 5 min with TBS-T before incubation with
1:1000 dilution of secondary antibody (anti-rabbit IgG, HRP-
conjugated antibody) (Chemicon, Boronia, Australia) for 1 h at
RT. Membranes were washed three times in TBS-T before
protein detection by enhanced chemiluminescence.
Flow cytometry was performed on siRNA-treated A431 cells
to identify levels of α6 integrin surface expression. siRNA-
treated and control cells were trypsinized from the plate and
washed once in full DMEM. They were then allowed to re-
express surface protein for 1 h at 37 °C in full DMEM with
gentle mixing every 15 min to prevent attachment to the tube.
Cells were washed once in cold PBS and fixed with 4%
paraformaldehyde for 20 min at RT before washing in PBS once
again. Staining for α6 integrin was performed by incubating
cells in the dark at 4 °C for 30 min with 10 μL neat FITC-labeled mouse-anti CD49f (α6 integrin) GoH3 antibody
(Serotec, Oxford, England) per 106 cells. Control antibody
staining was performed with an equivalent amount of FITC-
labeled mouse-anti rabbit IgG antibody (Rockland, Gilbetsville,
PA). Cells were then washed four times with cold PBS and
fluorescence analyzed using a BD Facscalibur flow cytometer.
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